Health Economics›Anaplastic glioma›Adjuvant therapy

Adjuvant therapy

Anaplastic glioma · 10 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Temozolomide and RT, then Temozolomide Variant #02	—	R 23 876	77d	—	—	—	—	—
Temozolomide, then Temozolomide and RT, then Temozolomide N/A - protocol	—	R 21 430	28d	—	—	—	—	—
Temozolomide and RT Variant #04	—	R 18 169	70d	~7.9 mo	~18.7 mo	~4	~R 72 677 PFS proxy · indirect	7
Temozolomide monotherapy Variant #13	—	R 8 153	28d	—	~8.6 mo	—	—	1
RT, then Temozolomide Variant #01	—	R 8 153	77d	—	—	—	—	2
PCV Variant #01 Partial	—	R 389	42d	—	~49.8 mo	—	—	2
RT, then Carmustine Variant #01 Partial	—	—	49d	—	—	—	—	—
Observation Partial	—	—	—	—	~31.2 mo	—	—	3
Carmustine monotherapy Variant #01 Partial	—	—	42d	—	—	—	—	—
Radiation therapy N/A - radiation Partial	—	—	49d	~46.0 mo	~7.5 mo	~29	—	8

10 of 10 regimens shown